Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) have announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.
Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA).
Sanofi Pasteur and MSD end joint vaccines business in Europe
- Details
- Category: Sanofi
Sanofi and its vaccines global business unit Sanofi Pasteur confirmed the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations.
AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer's disease (AD).
Merck drives business opportunities in the U.S. to foster innovation across all three business sectors
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced two collaborations in the metropolitan area of San Francisco, California (USA). The company is now cooperating with Palantir Technologies Inc., Palo Alto, California, and with the Stanford Graduate School of Business (Stanford GSB), Stanford, California.
FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC)
Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.
More Pharma News ...
- Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaboration
- Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes
- Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
- Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen
- Sanofi and Boehringer Ingelheim confirm Closing of business swap
- Top 20 World Pharma News of 2016
- Roche's emicizumab for haemophilia A meets primary endpoint in phase III study